Clinical trial
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic…
NCT00109200 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00109200 |
|---|---|
| Title | A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma |
| Official title | A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Xolair (omalizumab) |
| Start date | May 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Apr 26, 2005 |
| Last update posted | Jun 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: